A busy last quarter in 2024 for Partnership making
Paul O'Farrell
Finding Great Partners, Alliances, Customers in Pharma, Biotech & MedTech for Your Business
Its been a productive time for companies seeking partnerships and collaborations to build their business. Certainly the pace has been set recently by Samsung Biologics. They have just signed a deal for USD 1.24 billion with an asian pharma company which brings there total contract deal making for this year up to USD 3.3 billion! Another USD 3 Billion partnership has been announced between Novartis and PTC Therapeutics which is a mix of R&D activities and product licensing, more information on this is available below. Lots of smaller valued deals are covered in the newsletter.
In the December Newsletter I will break out recent announcements as follows:
It can be very confusing with the increased complexity of the types of companies now found in our sector. Recently I have seen the description #TechBio being used now to describe those companies offering drug discovery and/or drug development platforms in addition to the licensing of their NCE pipelines. Even more acronyms! I have included a curated collection of partnerships from the news feed on the site, if you would like to research more partnerships then go to https://www.pharmaservicesdirectory.com/news its possible to use the search engine to further define your search around your needs.
Partnerships Between CDMO's
Chinese Company, BGM Group Welcomes Guilin Pharma for On-site Audit and Partnership Development
BGM Group's?subsidiary Qilian Pharma hosted an on-site audit from Guilin Pharmaceutical experts on November 19, 2024. The audit aimed to establish future cooperation between the companies.....
Partnerships Between CDMO's
LBB Specialties and Clariant Partner to Distribute High-Quality Pharmaceutical Grade PEGs for Ophthalmic Applications
LBB Specialities Norwalk, CT, December 4, 2024 a leader in?speciality chemicals and ingredient distribution in North America, announced a strategic partnership with Clariant, a global leader in speciality chemical manufacturing. Through this collaboration, LBB Specialties will distribute Clariant’s pharmaceutical-grade high-functional excipients – including their polyethylene glycols (PEGs) and VitiPure? portfolio – for ophthalmic applications in the North American Life Sciences market.
Partnerships Between CDMO's
QVance Announces Partnership with Royale International to Drive Innovation
QVance has today announced that it has entered into a partnership with Royale International, a global leader in logistics and supply chain management. This collaboration marks a significant milestone in the development of end-to-end cold chain distribution and quality control analytical services solutions for the cell and gene therapy sector.
The partnership combines Royale International's extensive expertise in international shipping and logistics management with QVance's innovative solutions in quality analytical services for advanced therapies. Together, the two companies aim to address the need for personalised services for drug developers and manufacturers in the cold chain handling and release of cell and gene therapies across the Nordics and Europe.
Partnerships Between CDMO and Pharma/Bio
Samsung Biologics signs largest manufacturing deal with Asia-based pharmaceutical company
Samsung Biologics a global contract development and manufacturing organisation (CDMO), announced today a contract manufacturing deal with an Asia-based pharmaceutical company.? The disclosed deal, worth USD 1.24 billion, is the largest contract signed by a single client.....
Partnerships Between CDMO and Pharma/Bio
领英推荐
Treovir and Matica Bio Forms Strategic Partnership to Advance Innovative Therapies for Pediatric Brain Tumors
Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organisation (CDMO) specialising in viral vector development and manufacturing, today announced a strategic partnerships with Treovir. The collaboration aims to advance innovative therapies for paediatric patients with brain and other neurological cancers. Matica Bio will provide GMP manufacturing for clinical supplies.
?
Partnerships Between CDMO and Pharma/Bio
Smart Immune and CELLforCURE by SEQENS Partner to Industrialize SMART101 Clinical Batches Manufacturing
Smart Immune, a clinical-stage biotechnology company, and CELLforCURE by SEQENS, a Contract Development and Manufacturing Organization (CDMO) for Advanced Therapy Medical Products (ATMPs), announced today a strategic collaboration to expand SMART101 production capabilities. SMART101 is an innovative therapy in Phase I/II trials for patients with acute leukaemia or primary immunodeficiencies (PID), in the EU and the US.
Partnerships Between Pharma/Bio and Pharma/Bio
Novartis will partner with PTC Therapeutics with a $2.9 billion exclusive global license and collaboration agreement
Novartis will partner with PTC Therapeutics to expand the use of PTC’s small molecule splicing platform to develop PTC’s PTC518 Huntington’s disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license and collaboration agreement, the companies said today.
Partnerships Between Pharma/Bio and Pharma/Bio
Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery
Dundee, UK, and San Francisco, US, 15 October 2024: Ubiquigent Limited a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases. The partnership will combine Alleo’s AI-based approach to developing novel therapeutics with Ubiquigent’s platform and expertise in the field of DUB focused drug discovery. Financial details were not disclosed.
Partnerships Between Pharma/Bio and Pharma/Bio
ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals
CAMBRIDGE, Mass. and BERLIN, Germany -- November 14, 2024?— ARTBIO, Inc., a clinical-stage radio-pharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), and 3B Pharmaceuticals GmbH (3BP), a private biotechnology company developing targeted radio-pharmaceutical drugs and diagnostics for oncology indications, today announced a worldwide, exclusive license and research agreement to develop an advanced preclinical stage first-in-class peptide ART for the treatment of solid tumours.
If you would like to discuss collaborations and partnerships please get in contact through email at [email protected] or the website www.thepartnershiptree.com